PMID- 32665087
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 53
IP  - 1
DP  - 2021 Jan-Feb
TI  - Effect of Salvage Chemotherapy Before Donor Lymphocyte Infusion in Patients With 
      Relapse After Allogeneic Hematologic Stem Cell Transplantation.
PG  - 391-395
LID - S0041-1345(20)30422-X [pii]
LID - 10.1016/j.transproceed.2020.06.016 [doi]
AB  - OBJECTIVES: Allogeneic hematopoietic stem cell transplantation (AHSCT) is an 
      important treatment option in hematologic malignancies. Relapse after AHSCT is an 
      indicator of poor prognosis. These patients may be treated with donor lymphocyte 
      infusion (DLI). The chemotherapy given before DLI increases the success of the 
      treatment by reducing the burden of disease. The aim of this study is to 
      investigate post-DLI graft vs host disease (GvHD) and survival based on the 
      course of chemotherapy given before DLI. METHODS: A total of 23 patients who 
      received DLI because of relapsed disease after AHSCT were enrolled. All of the 
      patients received 1 or more courses of cytoreductive chemotherapy before DLI. 
      RESULTS: Complete remission (CR) after DLI remained in 78.2% of all patients. 
      There is no difference between 1 or multiple courses of chemotherapy in terms of 
      CR (55.6% vs 44.4%; P = .21). During follow-up after DLI, although it did not 
      reach statistical significance (P = .09), the patients receiving single-course 
      chemotherapy tended to have longer survival (36.1 vs 4.3 months, respectively). 
      Four patients who received multiple courses of chemotherapy were lost because of 
      infection-related disease (pneumonia, sepsis) while they were in CR. GvHD 
      development was more frequent in patients receiving multiple courses of 
      chemotherapies (60% of all GvHD patients). CONCLUSION: It has been demonstrated 
      that reducing the tumor burden by multiple-cycle chemotherapy does not have any 
      advantage in terms of CR and does not improve the overall survival.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Aladag, Elifcan
AU  - Aladag E
AD  - Faculty of Medicine, Department of Hematology, Hacettepe University, Ankara, 
      Turkey.
FAU - Goker, Hakan
AU  - Goker H
AD  - Faculty of Medicine, Department of Hematology, Hacettepe University, Ankara, 
      Turkey. Electronic address: hgoker1@yahoo.com.
FAU - Buyukasik, Yahya
AU  - Buyukasik Y
AD  - Faculty of Medicine, Department of Hematology, Hacettepe University, Ankara, 
      Turkey.
FAU - Demiroglu, Haluk
AU  - Demiroglu H
AD  - Faculty of Medicine, Department of Hematology, Hacettepe University, Ankara, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200711
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/*therapeutic use
MH  - Female
MH  - Graft vs Host Disease/etiology
MH  - Hematologic Neoplasms/pathology/*therapy
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Lymphocyte Transfusion/*methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/etiology/*therapy
MH  - Remission Induction
EDAT- 2020/07/16 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/05/17 00:00 [revised]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - S0041-1345(20)30422-X [pii]
AID - 10.1016/j.transproceed.2020.06.016 [doi]
PST - ppublish
SO  - Transplant Proc. 2021 Jan-Feb;53(1):391-395. doi: 
      10.1016/j.transproceed.2020.06.016. Epub 2020 Jul 11.